Cell & Gene Therapy Manufacturing Services Market Outlook:
Cell & Gene Therapy Manufacturing Services Market size was over USD 7.94 billion in 2025 and is anticipated to cross USD 40.86 billion by 2035, witnessing more than 17.8% CAGR during the forecast period i.e., between 2026-2035. In the year 2026, the industry size of cell & gene therapy manufacturing services is estimated at USD 9.21 billion.
The growth is majorly due to the rising demand for advanced therapies fueled by the increasing prevalence of conditions such as cancer, neurological disorders, and inherited diseases. Furthermore, automation, AI, and closed-system manufacturing processes are being adopted to enhance capabilities.
Governments worldwide are also providing regulatory support for faster approvals, and funding several research programs. This is encouraging biotech and pharma companies to develop cell and gene therapies. For instance, in October 2024, the 57th Governor of New York State funded USD 430 million, for New York BioGenesis Park which is a Cell and Gene Therapy Innovation Hub, in Long Island. As the therapies progress for clinical trials and toward commercialization, there’s a greater need for specialized manufacturing services to support their production.
